Abstract Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT). Optimal chemotherapy is unknown. We retrospectively analyzed outcomes of 58 patients treated with 2 cycles of high-dose ifosfamide and mitoxantrone (HDIM). HDIM consisted of ifosfamide 5 g/m 2 /day and MESNA 5 g/m 2 /day in continuous 24-h infusion (days 1 and 2), MESNA 2.5 g/m 2 over 12 h (day 3), and mitoxantrone 20 mg/m 2 (day 1) administered every 2 weeks. Stem cells were collected after the first cycle. Responding patients proceeded to ASCT. Toxicity was acceptable. Stem cell mobilization was successful in 96 % of patients. Overall response rate was 74 % (89 % in relapsing and 45 % in refractory patients) with 31 % complete remissions. After a median follow-up of 54 months, 5-year event-free survival was 56 % (69 % for relapsing and 35 % for refractory patients), and 5-year overall survival was 67 % (73 % for relapsing and 55 % for refractory patients). Significant adverse prognostic factors were refractoriness to previous therapy and HDIM failure. No differences in outcomes were noted between patients with early and late relapses or between complete and partial responders. HDIM is a well-tolerated and effective regimen for relapsed and refractory HL with excellent stem cell mobilizing properties. Patients failing HDIM may still benefit from other salvage options.
Introduction
Patients with relapsing or refractory Hodgkin's lymphoma (HL) are treated with salvage chemotherapy to induce remission and collect stem cells for autologous stem cell transplantation (ASCT) [1, 2] . Responding patients are subsequently autografted. ASCT is not effective in chemoresistant patients. Therefore, inducing a response is of paramount importance. The following different salvage chemotherapy regimens are usually used in this setting: miniBEAM (carmustine, etoposide, cytarabine, melfalan), dexaBEAM (dexamethasone + miniBEAM), DHAP (dexamethasone, cytarabine, cisplatin), ICE (ifosfamide, carboplatin, etoposide), GDP (gemcitabine, dexamethasone, cisplatin), and IGEV (ifosfamide, gemcitabine, etoposide, vinorelbine) [3] [4] [5] [6] [7] [8] [9] . Reported response rates and survival of these regimens are comparable. Patients who are refractory to front-line treatment (operationally defined as response lasting less than 3 months) have a significantly inferior prognosis. In some studies, patients relapsing less than 12 months from the end of front-line treatment (early relapses) fare worse than those relapsing later than 12 months since the end of treatment [6, 7] .
Salvage regimens consisting of high-dose ifosfamide and mitoxantrone were described in the 90s [10, 11] . We performed a phase II trial of a similar regimen with an intensified dose of ifosfamide (high-dose ifosfamide and mitoxantrone (HDIM)) for stem cell mobilization in patients with lymphoid malignancies and were favorably impressed by its antitumor activity [12] . HDIM has since been used as our standard salvage chemotherapy regimen in patients with relapsed or refractory HL eligible for ASCT. Here, we report a retrospective analysis of our experience in 58 patients treated between 2003 and 2015.
Patients and methods

Patients
Patients were eligible for inclusion in this analysis if they had relapsed or refractory HL, were at time of salvage treatment start eligible for ASCT, and were scheduled to receive 2 cycles of HDIM. We identified 58 patients by retrospective chart review. Their characteristics are presented in Table 1 . Twenty-one were refractory to prior treatment (duration of response to the last treatment less than 3 months), 19 were in early (duration of response to the last treatment 3-12 months), and 18 in late relapse (duration of response to the last treatment more than 12 months). None was known to be HIV positive. All patients were staged prior to treatment. Staging included careful palpation of peripheral nodes; CT scanning of the thorax, abdomen, and pelvis; and a bone marrow biopsy. PET was not used in all patients.
Treatment
HDIM consisted of ifosfamide 5 g/m 2 /day in continuous 24-h infusion for 2 days, MESNA 5 g/m 2 /day in continuous 24-h infusion for 2 days and 2.5 g/m 2 over 12 h on day 3, and mitoxantrone 20 mg/m 2 on day 1. G-CSF 10 μg/kg/day sc was started on day 6. At recovery, stem cells were collected by leukapheresis. A second cycle of HDIM was started on day 15 or after stem cell collection and hematologic recovery and was followed by G-CSF 5 μg/kg/day until leukocyte recovery. Patients with bone marrow infiltration were mobilized after the second HDIM cycle, provided that the repeated bone marrow biopsy was negative. Treatment was given in an in-patient setting. Patients were discharged after the end of chemotherapy and, if no complications occurred, readmitted for stem cell collection, chemotherapy, or ASCT. All received routine supportive care, including blood product transfusions and antiemetic prophylaxis with serotonin antagonists.
Patients with chemosensitive disease were autografted after conditioning with BEAM. Areas not in complete remission (CR) prior to ASCT were irradiated with 30-36 Gy after recovery from transplantation. Twenty patients received posttransplant radiotherapy.
Response assessment and follow-up
Restaging by CT scanning was performed after 2 cycles of HDIM. Response was determined according to the older, pre-PET, version of standard criteria [13] . CT or PET-CT was repeated after ASCT (or posttransplant radiotherapy). Patients who achieved remission were followed clinically, every 3 months for the first 3 years, every 6 months during the fourth and fifth years, and yearly thereafter. Imaging methods were repeated only if clinically indicated.
Overall (OS) and event-free survival (EFS) were calculated from the date of HDIM start until the last follow-up, death, or event, respectively. Events were defined as introduction of unplanned antitumor therapy due to lack of efficacy of HDIM, relapse, disease progression, or death.
Toxicity
Toxicity was analyzed by chart review and graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events v3.0. 
Ethics
This is a non-interventional retrospective study of patient data performed with the approval of the Ethical Committee of the Medical School, University of Zagreb, in accordance with pertinent Croatian, EU, and international rules and regulations and the Declaration of Helsinki. Prior to treatment, all patients gave informed consent for intensive chemotherapy and autologous stem cell transplantation.
Results
Toxicity
There was no treatment-related mortality. The second cycle was not administered in two patients, one due to progressive disease and the other due to toxicity. Median time to the start of second cycle was 16 days. As expected, hematological toxicity was universal. All patients developed severe granulocytopenia; 26 % needed platelet or red blood cell transfusions, and 73 % had fever or proven infections (Table 2) . Three patients had neurological side effects, one delirium, one seizures, and one syncope. One patient developed acute renal failure and received miniBEAM as the second cycle of therapy. Fourteen patients had nausea or vomiting, mostly while not receiving maximal prophylactic treatment; two had mucositis, three troublesome hiccups, one deep venous thrombosis, and one an algic syndrome. Thirty did not have any significant non-hematological and non-infectious side effects. All patients successfully recovered and none had to abstain from ASCT due to toxicity. As can be ascertained by routine clinical follow-up, no unusual symptomatic long-term toxicity was noted in survivors. A single patient developed secondary cancer (melanoma), and none had clinically manifest cardiac failure.
Stem cell collection
In two patients, stem cell collection was not performed due to HL progression. Stem cell collection was successful (>2 × 10 6 CD34
+ cells per kilogram body weight collected) in 54 patients (96 %). The remaining two failed to mobilize after HDIM but responded to plerixafor and were successfully autografted.
Hematologic recovery after ASCT was not delayed in comparison to patients that had been treated with miniBEAM or DHAP at our center.
Response to treatment and prognosis
After 2 cycles of HDIM, 18 patients achieved CR, 24 partial remission (PR), 11 had stable disease (SD), and 4 progressive disease (PD), for a response rate of 74 %. Data from restaging were not available for one patient. The response rate in primary refractory disease was significantly lower than in early and late relapse (45 vs. 89 %, respectively; p < 0.001).
In non-responders, different treatment regimens were tried (e.g., miniBEAM) in order to obtain a response and continue with autografting or allografting. Patients relapsing after ASCT were treated with DHAP; escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or gemcitabine + steroids. A single patient received brentuximab-vedotin; nine underwent allo-SCT.
After a median follow-up of survivors of 54 months (range 2-120 months), 16 patients (28 %) have died and 26 (45 %) had an event. Actuarial 5-year EFS of the whole group was 56 ± 7 % (95 % confidence interval) and OS 67 ± 7 %. EFS was significantly worse in refractory in comparison to early or late relapsing patients (5-year EFS 35 ± 10 vs. 67 ± 11 vs. 71 ± 11 %, respectively; p = 0.012; Fig. 1 ). The difference in OS was not statistically significant (5-year OS 55 ± 11 vs. 74 ± 12 vs. 72 ± 12 %, respectively; p = 0.131; Fig. 1 ). EFS and OS in early and late relapsing patients were similar. Beyond 5 years of follow-up, a single patient relapsed and none died.
We analyzed the impact of additional possible prognostic factors on EFS and OS. Gender, HL type, front-line regimen, previous radiotherapy, B symptoms, stage, and anemia did not influence outcomes. Response to HDIM was very important (Fig. 2) . Patients achieving CR had a 5-year EFS of 78 ± 10 %, PR 68 ± 10 %, SD 18 ± 12, and PD 0 % (CR and PR vs. SD and PD; p < 0.001). Median EFS was not reached in responding patients and was 6 and 2 months in the latter two groups, respectively. Patients achieving CR had a 5-year OS of 76 ± 11 %, PR 81 ± 9 %, SD 49 ± 17 %, and PD 25 ± 22 % 
Prognostic indices
The difference in EFS or OS between three prognostic groups defined by the original Josting's score (anemia, response duration <1 year, stages III and IV) was not significant (Table 3 ) [14] . EFS differed significantly between the favorable and unfavorable group but not between either of them and the intermediate group as defined by the modified Josting's score (anemia, response duration <1 year, stage IV) [6] . The difference in OS between these three groups was not significant. The index described by Moskowitz and coworkers (B symptoms, response duration <1 year, stage IV) was the only one able to divide patients into three groups with significantly different EFS and identify a favorable group with 100 % OS [7] .
Discussion
This is a retrospective study based on chart review. In comparison to prospective, controlled trials, this type of analysis could lead to underestimation of some types of toxicity and overestimation of efficacy. Lack of regular follow-up imaging might result in delayed identification of relapses. This should be kept in mind when comparing our results with those of prospective controlled studies. The toxicity of HDIM was acceptable, with a specter different from other salvage regimens [3] [4] [5] [6] [7] [8] [9] . Hematologic and infectious toxicity was very frequent but short. Renal side effects seem to be less severe than with DHAP (due to avoidance of cisplatinum) and duration of pancytopenia shorter than with miniBEAM or dexaBEAM. Neurological side effects occurring in three patients were probably related to highdose ifosfamide. All of them had refractory stage IV HL and severe systemic symptoms. HDIM is very emetogenic; 
p values refer to comparisons between prognostic groups indicated in the previous column 5-year EFS 5-year event-free survival intensive antiemetic prophylaxis is needed. The toxicity of the regimen is not cumulative; most patients tolerated the second cycle better than the first. HDIM had excellent mobilization potential. Only two patients who were not progressing on treatment failed to collect sufficient stem cells after HDIM but responded to plerixafor. These results are probably better than those achieved with miniBEAM or dexaBEAM and similar to those of ICE, GDP, IGEV, and DHAP.
Within the limitations imposed by the retrospective nature of the study, the antitumor activity of HDIM seems superior to miniBEAM and dexaBEAM and comparable to that of the newer regimens (Table 4) . A possible exception is IGEV, with a response of 81 % and a CR rate of 54 % [9] . However, EFS after IGEV is similar to that obtained using the other newer regimens, suggesting that the observed difference could be a consequence of evaluation at different time points (response evaluation of IGEV is performed after 4 cycles and of the other regimens after 2 cycles) and not of different antitumor activity. To our knowledge, no phase III trials comparing different chemotherapies (e.g., DHAP with ICE or similar) for pretransplant salvage therapy in HL have been performed. Therefore, as with large B cell lymphoma, all of these regimens can still be regarded as standard and probably equivalent. The choice between them will depend on need to avoid some types of toxicity (i.e., renal for DHAP and neurological for HDIM) and local expertise. Irrespective of this, outcome of relapsing or refractory patients receiving very aggressive front-line therapy such as eBEACOPP will be inferior to that reported.
The response to front-line therapy is the most important pretreatment prognostic factor. In all studies, including ours, refractory patients fared worse than relapsed. We did not find a difference in outcomes between late and early relapsing patients. This is in accordance with some [8, 9, 15 ] but in contrast to other studies [6, 7, 16] . The reason for this is not clear. Multiple studies have identified short response duration, extranodal disease, B symptoms, and anemia as negative prognostic factors. While the influence of any of these alone might not be very important, their combination seems to have additive effects. Patients with none have excellent, while those with three or more factors have a very poor prognosis. The index described by Moskowitz and coworkers was in our series superior to the modified Josting's index [6, 7] . The original Josting's score, with disease stages III and IV considered unfavorable, was not of prognostic significance [12] . A similar finding was reported previously in studies using dosedense therapy with ICE and DHAP [6, 7] . This suggests that short dose-dense treatment improves outcomes of nodal more than extranodal relapsed and refractory HL.
As in all other studies that analyzed it, response to salvage treatment was the most important prognostic factor. The outcome of patients with refractory disease who responded to HDIM was rather good, and more than half were cured with autografting (and radiotherapy in selected cases). Our experience indicates that patients with stable disease after salvage chemotherapy should not go on to ASCT. Only two of them did not relapse; both have received posttransplant radiotherapy. Recent studies suggest that PET-CT response evaluation prior to ASCT has an even better prognostic value and should be used to determine whether patients should proceed to transplant and/or receive posttransplant brentuximab consolidation [17, 18] .
Median OS in patients with SD after HDIM was longer than 3 years. This indicates that, even before the availability of brentuximab vedotin, non-cross-resistant chemotherapy treatment options existed for relapsed and refractory HL, and only patients progressing during treatment had a dismal prognosis. Some of those responding to subsequent lines of treatment can be cured with ASCT and radiotherapy. This is in accordance with the guidelines of the French Lymphoma Study Association [2] and results of Gerrie and coworkers [19] and in contrast to those of Villa and coworkers [20] . The outcome of this high-risk patient population can possibly additionally be improved with the use of double transplants or combinations of brentuximab with chemotherapy [21, 22] .
In conclusion, HDIM is an effective treatment for relapsed and refractory HL with acceptable toxicity and excellent mobilizing potential. It should be added to the armamentarium of salvage regimens for this type of lymphoma.
